Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Research

Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

Authors: Mohammed I. Oraby, Hatem A. El Masry, Sanaa S. Abd El Shafy, Esraa M. Abdul Galil

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Abstract

Background

Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The serum level of BDNF is altered in a diversity of neurological diseases. The aim of this work was to investigate the serum level of BDNF in patients with relapsing–remitting multiple sclerosis and the relation between BDNF and disease activity and severity.

Methods

A case–control study was conducted on 90 subjects: 60 patients with relapsing–remitting multiple sclerosis (30 in relapse and 30 in remission) on different lines of medical treatment and 30 healthy volunteers as a control. Clinical, functional, and radiological evaluation was done for the patients, and all the patients and controls were subjected to assessment of the serum level of BDNF by sandwich-ELISA technique.

Results

The BDNF level was significantly higher in MS patients in relapse than in patients in remission (P value = 0.006). In the remission group, there was no significant linear correlation between different MS patients’ characteristics and BDNF level, while in the relapse group, a positive linear correlation was found between the number of T2 infratentorial lesions and BDNF level (r = 0.402, P = 0.028). There was no statistically significant difference between the BDNF level in patients administered different drugs for MS in both remission and relapse groups (P value > 0.05).

Conclusion

BDNF was significantly higher in relapsing–remitting multiple sclerosis patients in the relapse phase. Attention should be paid to the link between serum BDNF level as a neuroprotective factor and multiple sclerosis; it can be a biomarker for MS activity in the near future.

Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48-49:134–42.CrossRef

Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188–97. https://doi.org/10.1056/NEJMoa1100648.CrossRefPubMedPubMedCentral

Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989;341(6238):149–52. https://doi.org/10.1038/341149a0.CrossRefPubMed

Gligoroska JP, Manchevska S. The effect of physical activity on cognition - physiological mechanisms. Mater Sociomed. 2012;24(3):198–202. https://doi.org/10.5455/msm.2012.24.198-202.CrossRefPubMedPubMedCentral

Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125(Pt 1):75–85. https://doi.org/10.1093/brain/awf015.CrossRefPubMed

Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545–64. https://doi.org/10.1098/rstb.2006.1894.CrossRefPubMedPubMedCentral

Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007;41(5):387–94. https://doi.org/10.1016/j.jpsychires.2006.01.014.CrossRefPubMed

Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P, Telarico P, Cerasa A, Gioia MC, di Palma G, Quattrone A. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing–remitting multiple sclerosis. Brain Res. 2009;1256:123–8. https://doi.org/10.1016/j.brainres.2008.11.047.CrossRefPubMed

Vondran MW, Clinton-Luke P, Honeywell JZ, Dreyfus CF. BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain. Glia. 2010;58(7):848–56. https://doi.org/10.1002/glia.20969.CrossRefPubMedPubMedCentral

10.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

11.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52. https://doi.org/10.1212/WNL.33.11.1444.CrossRefPubMed

12.

Bruck W, Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol. 2005;18(3):221–4. https://doi.org/10.1097/01.wco.0000169736.60922.20.CrossRefPubMed

13.

Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol. 2003;53(3):292–304. https://doi.org/10.1002/ana.10446.CrossRefPubMed

14.

Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol. 2002;132(1-2):180–8. https://doi.org/10.1016/S0165-5728(02)00319-3.CrossRefPubMed

15.

Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett. 2009;460(2):130–2. https://doi.org/10.1016/j.neulet.2009.05.057.CrossRefPubMed

16.

Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005;167(1-2):215–8. https://doi.org/10.1016/j.jneuroim.2005.07.001.CrossRefPubMed

17.

Comini-Frota ER, Rodrigues DH, Miranda EC, Brum DG, Kaimen-Maciel DR, Donadi EA, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with the number of T2 MRI lesions in multiple sclerosis. Braz J Med Biol Res. 2012;45(1):68–71. https://doi.org/10.1590/S0100-879X2011007500165.CrossRefPubMed

18.

Kalinowska-Łyszczarz A, Pawlak MA, Wyciszkiewicz A, Osztynowicz K, Kozubski W, Michalak S. Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy. Neurol Neurochir Pol. 2018;52(4):483–9. https://doi.org/10.1016/j.pjnns.2018.03.006.CrossRefPubMed

19.

Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol. 2008;195(1-2):186–93. https://doi.org/10.1016/j.jneuroim.2008.01.010.CrossRefPubMed

20.

kint M, Heyman EM, Meeusen R. Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects. Sports Med. 2010;40(9):765–801. https://doi.org/10.2165/11534530-000000000-00000.

21.

Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R. Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017;103(3):237–41. https://doi.org/10.1016/j.yexmp.2017.11.004.CrossRefPubMed

22.

Petereit HF, Lindemann H, Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler. 2003;9(1):16–20. https://doi.org/10.1191/1352458503ms869oa.CrossRefPubMed

23.

Liguori M, Fera F, Gioia MC, Valentino P, Manna I, Condino F, Cerasa A, la Russa A, Clodomiro A, Paolillo A, Nisticò R, Vercillo L, Cittadella R, Quattrone A. Investigating the role of brain-derived neurotrophic factor in relapsing–remitting multiple sclerosis. Genes Brain Behav. 2007;6(2):177–83. https://doi.org/10.1111/j.1601-183X.2006.00245.x.CrossRefPubMed

24.

Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37(12):1553–61. https://doi.org/10.1016/S0028-3908(98)00141-5.CrossRefPubMed

25.

Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol. 2006;118(1):77–82. https://doi.org/10.1016/j.clim.2005.09.005.CrossRefPubMed

26.

Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, Tenaglia S, di Filippo M, Calabresi P. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler. 2007;13(3):313–31. https://doi.org/10.1177/1352458506070146.CrossRefPubMed

27.

Fernández-Jiménez E, Arnett PA. Impact of neurological impairment, depression, cognitive function and coping on quality of life of people with multiple sclerosis: a relative importance analysis. Mult Scler. 2015;21(11):1468–72. https://doi.org/10.1177/1352458514562439.CrossRefPubMed

28.

Yoshimura S, Ochi H, Isobe N, Matsushita T, Motomura K, Matsuoka T, Minohara M, Kira JI. Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Mult Scler. 2010;16(10):1178–88. https://doi.org/10.1177/1352458510375706.CrossRefPubMed

29.

Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, de Stefano N. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol. 2007;64(8):1157–61. https://doi.org/10.1001/archneur.64.8.1157.CrossRefPubMed

30.

Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236–42. https://doi.org/10.1002/ana.20883.CrossRefPubMed

31.

Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15(3):239–45. https://doi.org/10.1097/00019052-200206000-00003.CrossRefPubMed

32.

Almutairi A, Hassan H, Suppiah S, Alomair O, Alshoaibi A, Almutairi H, et al. Lesion load assessment among multiple sclerosis patient using DIR, FLAIR, and T2WI sequences. Egypt J Radiol Nucl Med. 2020;51(1):209. https://doi.org/10.1186/s43055-020-00312-0.CrossRef

33.

Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007;13(4):459–70. https://doi.org/10.1177/1352458506069672.CrossRefPubMed

34.

Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol. 2008;197(2):147–51. https://doi.org/10.1016/j.jneuroim.2008.04.033.CrossRefPubMed

35.

Mehrpour M, Akhoundi FH, Delgosha M, Keyvani H, Motamed MR, Sheibani B, Meysamie A. Increased serum brain derived neurotrophic factor in multiple sclerosis patients on interferon-b and its impact on functional abilities. Neurologist. 2015;20(4):57–60. https://doi.org/10.1097/NRL.0000000000000053.CrossRefPubMed

Title: Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity
Authors: Mohammed I. Oraby
Hatem A. El Masry
Sanaa S. Abd El Shafy
Esraa M. Abdul Galil
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
Biomarkers
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00296-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Predictors of parenting stress in parents of children diagnosed with autism spectrum disorder: a scoping review

The efficacy of ultrasound-guided multifidus cervicis plane block versus greater occipital nerve block for cervicogenic headache

Obsessive–compulsive disorder post-COVID-19: a case presentation

Epidemiological profile of psychiatric illnesses in the province of Taza, Morocco: case of a study on a schizophrenic sub-population in the Ibn Baja Hospital

Exploring the factors associated with coronaphobia among physicians during the COVID-19 outbreak in Egypt

Depression among health workers caring for patients with COVID-19 in Egypt